Practice Pearls

What can we help you find?
Practice Pearl 1: Addressing Reluctance to Use SQ Dosing
Potential clinical and financial causes for hesitation in the transition to subcutaneous dosing are addressed.
Practice Pearl 1: Educating Staff on SQ Dosing
Experts provide perspective on how they prepare their staff for the transition to subcutaneous dosing.
Practice Pearl 1: Impact of Subcutaneous Dosing Preparation
The differences in subcutaneous formulation preparation and the corresponding impact on practice.
Practice Pearl 1: The Benefits of a Flat Dose
Experts consider the reasoning behind flat dosing of subcutaneous formulations, as well as its added benefit.
The iStopMM Trial & Importance of Early Screening
Key opinion leaders discuss the iStopMM study and the importance of early screening.
The Role of Payers in the Dispensing Process
A discussion on the role of payers in the oral oncolytic dispensing process.
The Future of Oral Oncolytics
Expert panelists consider the future of the treatment of multiple myeloma, with oral oncolytics being the standard of therapy.
Pearl 4: Using a Collaborative Care Plan for the Treatment of MM
The panelists discuss the collaborative care plan in place for providing patients with the optimal treatment of multiple myeloma.
Difficulties of the Multiple Myeloma Treatment Continuum
Key opinion leaders expand upon the difficulties that arise from the oral oncolytic dispensary system, including the inadequacy of community centers, time-consuming documentation, the appropriate utilization contingencies, and more.
The Role of Specialty Pharmacies in the Dispensing Process
A discussion on the role of specialty pharmacies in the oral oncolytic distribution process and the difficulties of patients who are geographically challenged.
The Dispensing Capabilities of Pharmacies
Peter Salgo, MD, et al., consider the dispensing capabilities of pharmacies in addition to 7-days-off treatment plans.
Pearl 3: Avoiding Delays During Prior Authorization Process
Key opinion leaders discuss the policy of prior authorization and how it may affect the timely delivery of oral oncolytic therapy.
+ Load More